WO2008013816A2 - Tat-051 et procédés d'évaluation et de traitement du cancer - Google Patents

Tat-051 et procédés d'évaluation et de traitement du cancer Download PDF

Info

Publication number
WO2008013816A2
WO2008013816A2 PCT/US2007/016656 US2007016656W WO2008013816A2 WO 2008013816 A2 WO2008013816 A2 WO 2008013816A2 US 2007016656 W US2007016656 W US 2007016656W WO 2008013816 A2 WO2008013816 A2 WO 2008013816A2
Authority
WO
WIPO (PCT)
Prior art keywords
tat
polypeptide
nucleic acid
antibody
cancer
Prior art date
Application number
PCT/US2007/016656
Other languages
English (en)
Other versions
WO2008013816A3 (fr
Inventor
Daniel Chelsky
Patrice Hugo
Leslie H. Kondejewski
Lyes Hamaidi
Joel Lanoix
Eustache Paramithiotis
Paul E. Kearney
David Mcelligott
Scott R. Peterson
Christopher Mark Hill
Original Assignee
Thallion Pharmaceuticals, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thallion Pharmaceuticals, Incorporated filed Critical Thallion Pharmaceuticals, Incorporated
Publication of WO2008013816A2 publication Critical patent/WO2008013816A2/fr
Publication of WO2008013816A3 publication Critical patent/WO2008013816A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

Contre toute attente, les présents inventeurs ont découvert que l'expression de la protéine TAT- 051 chez les patients humains était associée au cancer, et que la sur-expression de la protéine était présente dans des fractions de la membrane plasmatique. Les présents inventeurs ont donc découvert que la protéine TAT-051 était associée à un développement et à une croissance anormaux. De plus, des polypeptides TAT-051, des acides nucléiques TAT-051 et des anticorps anti-TAT-051 ont été générés. Par conséquent, la présente invention concerne des procédés de diagnostic d'une maladie associée à la protéine TAT-051, comme le cancer (le cancer du poumon, par exemple) en utilisant les polypeptides TAT-051, les acides nucléiques TAT-051 et les anticorps anti-TAT-051 de l'invention. En outre, les polypeptides TAT-051, les acides nucléiques TAT-051 et les anticorps anti-TAT-051 de l'invention peuvent être utilisés pour traiter un animal souffrant d'une maladie associée à la protéine TAT-051, comme le cancer (le cancer du poumon, par exemple). Dans d'autres modes de réalisation, les polypeptides TAT-051 et les acides nucléiques TAT-051 peuvent être utilisés comme cible pour l'identification de composés anti-cancéreux, notamment des anticorps à utiliser en immunothérapie et des composés qui inhibent l'expression ou l'activité de la protéine TAT-051.
PCT/US2007/016656 2006-07-24 2007-07-24 Tat-051 et procédés d'évaluation et de traitement du cancer WO2008013816A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83293606P 2006-07-24 2006-07-24
US60/832,936 2006-07-24

Publications (2)

Publication Number Publication Date
WO2008013816A2 true WO2008013816A2 (fr) 2008-01-31
WO2008013816A3 WO2008013816A3 (fr) 2008-10-16

Family

ID=38982029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016656 WO2008013816A2 (fr) 2006-07-24 2007-07-24 Tat-051 et procédés d'évaluation et de traitement du cancer

Country Status (1)

Country Link
WO (1) WO2008013816A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043807A2 (fr) * 1998-02-25 1999-09-02 Incyte Pharmaceuticals, Inc. Molecules liees aux canaux humains

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043807A2 (fr) * 1998-02-25 1999-09-02 Incyte Pharmaceuticals, Inc. Molecules liees aux canaux humains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRACKELTON ET AL.: 'Evidence for the platelet-derived growth factor-stimulated tyrosine phosphorylation of the platelet-derived growth factor receptor in vivo. Immunopurification using a monoclonal antibody to phosphotyrosine' J. BIOL. CHEM. vol. 259, no. 12, 25 June 1984, pages 7909 - 7915, XP001038117 *
SACCHI ET AL.: 'Ligand-induced phosphorylation of a murine tumor surface protein (TSP-180) associated with metastatic phenotype' CANCER RES. vol. 49, no. 10, 15 May 1989, pages 2615 - 2620 *

Also Published As

Publication number Publication date
WO2008013816A3 (fr) 2008-10-16

Similar Documents

Publication Publication Date Title
US7998689B2 (en) Detection of CXADR protein for diagnosis of kidney cancer
US7842466B1 (en) Colon disease targets and uses thereof
US7521195B1 (en) Lung disease targets and uses thereof
US20200325189A1 (en) Colon disease targets and uses thereof
US20150132286A1 (en) Pancreatic cancer targets and uses thereof
KR20110052642A (ko) 결장직장암의 검출 및 치료를 위한 조성물
US20070106065A1 (en) TAT- 001 and methods of assessing and treating cancer
JP2010101901A (ja) 癌に関与するタンパク質
US20070192887A1 (en) TAT-042 and methods of assessing and treating cancer
US20070269434A1 (en) TAT-041 and methods of assessing and treating cancer
US20070186294A1 (en) TAT-030 and methods of assessing and treating cancer
US20070192884A1 (en) TAT-038 and methods of assessing and treating cancer
US20070180545A1 (en) TAT-031 and methods of assessing and treating cancer
US20100183630A1 (en) Tat-005 and Methods of Assessing and Treating Cancer
US20070192885A1 (en) TAT-039 and methods of assessing and treating cancer
US20070186295A1 (en) TAT-036 and methods of assessing and treating cancer
US20070192883A1 (en) TAT-028 and methods of assessing and treating cancer
US20070192886A1 (en) TAT-044 and methods of assessing and treating cancer
US20070220620A1 (en) TAT-046 and methods of assessing and treating cancer
WO2006133145A2 (fr) Tat-007 et procédés d'évaluation et de traitement de cancer
WO2006116681A2 (fr) Tat-003 et procedes de determination et de traitement du cancer
WO2008013816A2 (fr) Tat-051 et procédés d'évaluation et de traitement du cancer
WO2006116541A2 (fr) Tat-002 et procedes pour evaluer et traiter un cancer
WO2008010980A2 (fr) Tat-049 et procédés d'évaluation et de traitement du cancer
WO2008005556A2 (fr) Tat-048 et procédé d'évaluation et de traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07810731

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07810731

Country of ref document: EP

Kind code of ref document: A2